Literature DB >> 2168404

Tumor necrosis factors-alpha and -beta bind to the same two types of tumor necrosis factor receptors and maximally activate the transcription factor NF-kappa B at low receptor occupancy and within minutes after receptor binding.

H P Hohmann1, R Remy, B Pöschl, A P van Loon.   

Abstract

HL60 cells have types A and B tumor necrosis factor (TNF) receptors whereas HEp2 cells have only the type B receptor (Hohmann, H.-P., Remy, R., Brockhaus, M., and van Loon, A.P.G.M. (1989) J. Biol. Chem. 264, 14927-14934). TNF-beta can be cross-linked to each of these receptors and competes with TNF-alpha for binding to both receptors. TNF-alpha and TNF-beta activate the transcription factor NF-kappa B in HL60 and HEp2 cells. Maximal activation of NF-kappa B required binding of TNF-alpha or TNF-beta to 20-25% of the total number of TNF receptors and was achieved within minutes after the addition of TNF-alpha to HL60 cells. Both TNF-alpha and TNF-beta activate NF-kappa B at 5-10-fold lower concentrations in HL60 cells compared with HEp2 cells, and this correlates well with their different affinities for binding to these cells. Thus, TNF-alpha and TNF-beta are indistinguishable with respect to the correlation between degrees of receptor binding and activation of NF-kappa B.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2168404

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement.

Authors:  B J Czermak; A B Lentsch; N M Bless; H Schmal; H P Friedl; P A Ward
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

Review 2.  Cytokines, receptors, and inhibitors.

Authors:  G Gehr; T Braun; W Lesslauer
Journal:  Clin Investig       Date:  1992-01

Review 3.  Immunoregulation by tumor necrosis factor superfamily member LIGHT.

Authors:  Yugang Wang; Mingzhao Zhu; Mendy Miller; Yang-Xin Fu
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 4.  Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy.

Authors:  Haidong Tang; Mingzhao Zhu; Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2017-04-17       Impact factor: 11.530

5.  Increased expression and occupancy of receptors for tumour necrosis factor on blood monocytes from tuberculosis patients.

Authors:  J Cadranel; C Philippe; B Philippe; B Milleron; B Fouqueray; C Mayaud; L Baud
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

6.  Identification of key processes that control tumor necrosis factor availability in a tuberculosis granuloma.

Authors:  Mohammad Fallahi-Sichani; Matthew A Schaller; Denise E Kirschner; Steven L Kunkel; Jennifer J Linderman
Journal:  PLoS Comput Biol       Date:  2010-05-06       Impact factor: 4.475

7.  Irradiation up-regulates CD80 expression through induction of tumour necrosis factor-alpha and CD40 ligand expression on B lymphoma cells.

Authors:  Fumio Ishikawa; Hideki Nakano; Akira Seo; Yayoi Okada; Hideko Torihata; Yuriko Tanaka; Tetsuya Uchida; Hidekazu Miyake; Terutaka Kakiuchi
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

Review 8.  Tumor necrosis factor receptors--structure and function.

Authors:  J Rothe; G Gehr; H Loetscher; W Lesslauer
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

9.  Activation of apoptosis by 1-hydroxy-5,7-dimethoxy-2-naphthalene-carboxaldehyde, a novel compound from Aegle marmelos.

Authors:  Dharmalingam Subramaniam; Periyasamy Giridharan; Nabendu Murmu; Nallakandy P Shankaranarayanan; Randal May; Courtney W Houchen; Rama P Ramanujam; Arun Balakrishnan; Ram A Vishwakarma; Shrikant Anant
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

10.  Endothelial activation by hydrogen peroxide. Selective increases of intercellular adhesion molecule-1 and major histocompatibility complex class I.

Authors:  J R Bradley; D R Johnson; J S Pober
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.